Once scored as a po­ten­tial block­buster, No­var­tis’ sere­lax­in fiz­zles in crit­i­cal car­dio out­comes test

You can scratch sere­lax­in off No­var­tis’ list of po­ten­tial block­busters in the late-stage pipeline.

This morn­ing the phar­ma gi­ant said that its 4-year study of the heart drug flubbed the pri­ma­ry end­point, fail­ing to sig­nif­i­cant­ly cut the rate of car­dio­vas­cu­lar death or re­duce wors­en­ing heart fail­ure among pa­tients with acute heart fail­ure.

No­var­tis Chief Med­ical Of­fi­cer Vas Narasimhan said that the phar­ma gi­ant will con­tin­ue to look over the da­ta to de­ter­mine next steps. But the R&D jour­ney would ap­pear to be over.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER